News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,395 Results
Type
Article (8029)
Company Profile (142)
Press Release (478493)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166749)
Career Advice (304)
Deals (25743)
Drug Delivery (7)
Drug Development (52881)
Employer Resources (14)
FDA (9760)
Job Trends (8573)
News (238212)
Policy (17903)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (491)
Accelerated approval (27)
ADA (18)
Adcomms (1)
Allergies (99)
Alliances (33146)
ALS (114)
Alzheimer's disease (989)
Antibody-drug conjugate (ADC) (295)
Approvals (10418)
Artificial intelligence (345)
ASCO (160)
Autoimmune disease (228)
Automation (30)
Bankruptcy (263)
Belgium (3)
Best Places to Work (6952)
BIO (36)
Biologics (14)
BIOSECURE Act (1)
Biosimilars (119)
BioSpace Insights (17)
Biotechnology (90)
Bispecific (3)
Bladder cancer (140)
Brain cancer (33)
Breast cancer (522)
Cancer (3832)
Cardiovascular disease (230)
Career advice (242)
Career pathing (1)
CAR-T (182)
CDC (1)
CDMO (21)
Celiac Disease (1)
Cell therapy (497)
Cervical cancer (35)
Clinical research (48097)
Collaboration (1307)
Commercialization (6)
Compensation (1552)
Complete response letters (35)
COVID-19 (763)
CRISPR (65)
C-suite (821)
Cystic fibrosis (87)
Data (5997)
Denatured (4)
Depression (108)
Dermatology (80)
Diabetes (364)
Diagnostics (4230)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (162)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (171)
Earnings (73777)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88235)
Executive appointments (721)
FDA (12540)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (19)
Frontotemporal dementia (24)
Funding (971)
Gene editing (127)
Generative AI (11)
Gene therapy (340)
GLP-1 (299)
Government (944)
Grass and pollen (2)
Guidances (281)
Healthcare (9365)
Hematology (94)
HIV (55)
Huntington's disease (23)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (70)
Immunology and inflammation (112)
Immuno-oncology (62)
Indications (169)
Infectious disease (957)
Inflammatory bowel disease (131)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (266)
Interviews (41)
IPO (12394)
IRA (2)
Job creations (1968)
Job search strategy (232)
JPM (1)
Kidney cancer (17)
Kidney disease (47)
Layoffs (59)
Legal (5194)
Licensing (24)
Liver cancer (46)
Longevity (20)
Lung cancer (555)
Lung diease (8)
Lymphoma (261)
Machine learning (29)
Management (3)
Manufacturing (587)
Marketing (9)
MASH (118)
Medical affairs (2)
Medical device (8691)
Medtech (8854)
Mergers & acquisitions (14424)
Metabolic disorders (740)
mRNA (69)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (229)
Neuropsychiatric disorders (40)
Neuroscience (1891)
NextGen: Class of 2026 (3147)
Non-profit (843)
Obesity (235)
Opinion (10)
Ovarian cancer (169)
Pain (179)
Pancreatic cancer (213)
Parkinson's disease (211)
Partnered (12)
Patents (509)
Patient advocacy (1)
Patient recruitment (534)
Patient selection (14)
Peanut (33)
People (41408)
Peptides (5)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15538)
Phase 2 (21489)
Phase 3 (14486)
Pipeline (7947)
Policy (18)
Postmarket research (1559)
Preclinical (6561)
Press Release (34)
Prostate cancer (196)
Psychedelics (9)
Radiopharmaceuticals (198)
Rare diseases (601)
Real estate (3023)
Recruiting (6)
Regenerative medicine (7)
Regulatory (15026)
Reports (23)
Research institute (586)
Resumes & cover letters (45)
Rett syndrome (44)
RNA editing (7)
RSV (48)
Schizophrenia (104)
Series A (170)
Series B (125)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (91)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (51)
Vaccines (322)
Venture capital (17)
Weight loss (76)
Wet AMD (1)
Women's health (91)
Date
Last 7 days (351)
Last 30 days (1300)
Last 365 days (19030)
2026 (14261)
2025 (19239)
2024 (22988)
2023 (26538)
2022 (34592)
2021 (37151)
2020 (33447)
2019 (23239)
2018 (17478)
2017 (18772)
2016 (17901)
2015 (24265)
2014 (21679)
2013 (18128)
2012 (20222)
2011 (20430)
2010 (20316)
Location
Africa (229)
Alabama (80)
Alaska (2)
Arizona (313)
Arkansas (11)
Asia (18024)
Australia (2110)
California (12518)
Canada (3284)
China (556)
Colorado (509)
Connecticut (435)
Delaware (218)
Europe (24728)
Florida (1885)
Georgia (396)
Hawaii (3)
Idaho (46)
Illinois (740)
India (55)
Indiana (326)
Iowa (16)
Japan (437)
Kansas (104)
Kentucky (33)
Louisiana (27)
Maine (27)
Maryland (1245)
Massachusetts (8196)
Michigan (315)
Minnesota (578)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (125)
New Hampshire (60)
New Jersey (2747)
New Mexico (12)
New York (2938)
North Carolina (1325)
North Dakota (4)
Northern California (6300)
Ohio (298)
Oklahoma (14)
Oregon (16)
Pennsylvania (2329)
Puerto Rico (24)
Rhode Island (30)
South America (407)
South Carolina (78)
South Dakota (1)
Southern California (5221)
Tennessee (125)
Texas (2053)
United States (40579)
Utah (377)
Vermont (1)
Virginia (160)
Washington D.C. (39)
Washington State (967)
West Virginia (1)
Wisconsin (78)
Wyoming (1)
486,395 Results for "ascletis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
September 8, 2026
·
5 min read
Press Releases
Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
September 7, 2026
·
3 min read
Press Releases
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis’ Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
September 30, 2026
·
11 min read
Press Releases
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
August 30, 2026
·
6 min read
Press Releases
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
September 28, 2026
·
5 min read
Press Releases
Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
July 27, 2026
·
4 min read
Press Releases
Ascletis to Present Data on Multiple Programs at the American Diabetes Association’s 2026 Scientific Sessions
April 29, 2026
·
2 min read
Press Releases
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
May 6, 2026
·
3 min read
Press Releases
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
July 15, 2026
·
4 min read
Press Releases
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
July 23, 2026
·
3 min read
1 of 48,640
Next
